Cui et al. reported a pioneering study using CD38-directed CAR-T cells in 6 patients with relapsed CD38+ AML after allo-HCT, and 4 (66.7%) achieved CR or CR with incomplete count recovery (CRi) (123). This evidence concerns the gene CD38 and acute myeloid leukemia.